Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed, the hematological benefit during eculizumab t...

Повний опис

Бібліографічні деталі

Автори:	Antonio M. Risitano, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2019-06-01
Серія:	Frontiers in Immunology
Предмети:	paroxysmal nocturnal hemoglobinuria intravascular hemolysis extravascular hemolysis complement inhibition eculizumab ravulizumab
Онлайн доступ:	https://www.frontiersin.org/article/10.3389/fimmu.2019.01157/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!